Clicky

PAVmed Inc. Series Z Warrant(PAVMZ)

Description: PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.


Keywords:

Home Page: www.pavmed.com

360 Madison Avenue
New York, NY 10017
United States
Phone: 917-813-1828


Officers

Name Title
Dr. Lishan Aklog M.D. Chairman & CEO
Mr. Dennis M. McGrath CPA President & CFO
Mr. Shaun M. O'Neill M.B.A. Executive VP & COO
Mr. Michael Adam Gordon Executive VP, General Counsel & Secretary
Dr. Brian J. deGuzman M.D. Executive VP, Chief Technology & Compliance Officer
Dr. Suman M. Verma M.D., Ph.D. Senior VP of Molecular Genetics & Chief Scientific Officer
Michael Parks Vice President of Investor Relations
Dr. Deepika A. Lakhani Ph.D. Senior VP, Chief Regulatory & Quality Officer
Dr. Victoria T. Lee M.D. Senior VP & Chief Medical Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0
IPO Date: 2018-04-10
Fiscal Year End: December
Full Time Employees: 107
Back to stocks